keyword
MENU ▼
Read by QxMD icon Read
search

Anti-platelets

keyword
https://www.readbyqxmd.com/read/29774732/management-of-peridural-catheter-removal-during-dual-anti-platelet-therapy-after-postoperative-myocardial-infarction-and-drug-eluting-stent-implantation-applying-the-bridging-therapy-concept
#1
Tindaro Mogavero, Rocco Pace, Luigi Vetrugno
No abstract text is available yet for this article.
May 15, 2018: Minerva Anestesiologica
https://www.readbyqxmd.com/read/29760702/emerging-concepts-in-immune-thrombocytopenia
#2
REVIEW
Maurice Swinkels, Maaike Rijkers, Jan Voorberg, Gestur Vidarsson, Frank W G Leebeek, A J Gerard Jansen
Immune thrombocytopenia (ITP) is an autoimmune disease defined by low platelet counts which presents with an increased bleeding risk. Several genetic risk factors (e.g., polymorphisms in immunity-related genes) predispose to ITP. Autoantibodies and cytotoxic CD8+ T cells (Tc) mediate the anti-platelet response leading to thrombocytopenia. Both effector arms enhance platelet clearance through phagocytosis by splenic macrophages or dendritic cells and by induction of apoptosis. Meanwhile, platelet production is inhibited by CD8+ Tc targeting megakaryocytes in the bone marrow...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/29754562/cardiology-electronic-consultation-e-consult-use-by-primary-care-providers-at-va-medical-centres-in-new-england
#3
Eun Ji Kim, Jay D Orlander, Melissa Afable, Sumeet Pawar, Sarah L Cutrona, Steven R Simon, Judith Strymish, Varsha G Vimalananda
Introduction E-consultations (e-consults) were implemented at VA medical centers to improve access to specialty care. Cardiology e-consults are among the most commonly requested, but little is known about how primary care providers (PCPs) use cardiology e-consults to access specialty care. Methods This is a retrospective analysis of 750 patients' medical charts with cardiology e-consults requested by medical providers (October 2013-September 2015) in the VA New England Healthcare System. We described the patients and referring provider characteristics, and e-consult questions...
January 1, 2018: Journal of Telemedicine and Telecare
https://www.readbyqxmd.com/read/29749594/-non-aneurysmal-subarachnoid-haemorrhage-secondary-to-panarteritis-nodosa-at-paediatric-age-a-case-report
#4
L Salgado-Lopez, C de Quintana-Schmidt, I Catala-Antunez, J Aibar-Duran, L San Roman-Manzanera, J Molet-Teixido
INTRODUCTION: Polyarteritis nodosa is a necrotizing vasculitis that mainly affects small and medium-sized arteries in skin and internal organs. Neurological involvement is reported in around 25% of cases: ischemic stroke is relatively common, but haemorrhagic lesions are extremely rare. Subarachnoid haemorrhage in polyarteritis nodosa is an uncommon expression of this disease, mostly associated with aneurism rupture. To the best of the authors' knowledge, there is just one published case in pediatric age with polyarteritis nodosa and subarachnoid haemorrhage with no underlying aneurismal disease...
May 16, 2018: Revista de Neurologia
https://www.readbyqxmd.com/read/29742480/clinical-benefits-and-pharmacology-of-scutellarin-a-comprehensive-review
#5
REVIEW
Liping Wang, Qiang Ma
Stroke and myocardial infarction are among the most common causes of mortality and disability in the world. The ischemic injury underlying these illnesses is complex, involving intricate interplays among many biological functions including energy metabolism, vascular regulation, hemodynamics, oxidative stress, inflammation, platelet activation, and tissue repair that take place in a context- and time-dependent manner. The current drug therapy of choice is to timely resupply the blood to the ischemic tissue; but reperfusion may introduce additional harm to the tissue through a process known as ischemia/reperfusion injury...
May 6, 2018: Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29731231/structural-properties-of-the-human-protease-activated-receptor-1-changing-by-a-strong-antagonist
#6
Patrizia M Spoerri, Hideaki E Kato, Moritz Pfreundschuh, Stefania A Mari, Tetiana Serdiuk, Johannes Thoma, K Tanuj Sapra, Cheng Zhang, Brian K Kobilka, Daniel J Müller
The protease-activated receptor 1 (PAR1), a G protein-coupled receptor (GPCR) involved in hemostasis, thrombosis, and inflammation, is activated by thrombin or other coagulation proteases. This activation is inhibited by the irreversible antagonist vorapaxar used for anti-platelet therapy. Despite detailed structural and functional information, how vorapaxar binding alters the structural properties of PAR1 to prevent activation is hardly known. Here we apply dynamic single-molecule force spectroscopy to characterize how vorapaxar binding changes the mechanical, kinetic, and energetic properties of human PAR1 under physiologically relevant conditions...
April 17, 2018: Structure
https://www.readbyqxmd.com/read/29728446/tas05567-a-novel-potent-and-selective-spleen-tyrosine-kinase-inhibitor-abrogates-immunoglobulin-mediated-autoimmune-and-allergic-reactions-in-rodent-models
#7
Hiroaki Hayashi, Ryusuke Kaneko, Shunsuke Demizu, Daichi Akasaka, Manabu Tayama, Takafumi Harada, Hiroki Irie, Yoshio Ogino, Naoko Fujino, Eiji Sasaki
Spleen tyrosine kinase (Syk) is involved in regulation of B-cell receptor (BCR) and Fc receptor (FcR) downstream signal pathways. Syk plays an essential role in production of inflammatory mediators and differentiation in various immune cells and is therefore an attractive target for treating inflammatory conditions, such as autoimmune and allergic diseases. We identified TAS05567 as a highly selective Syk inhibitor and evaluated its therapeutic potential in animal models. In vitro biochemical assays were performed with available kinase assay panels...
May 4, 2018: Journal of Pharmacology and Experimental Therapeutics
https://www.readbyqxmd.com/read/29728030/-effect-of-compatibility-of-ginkgolide-a-ginkgolide-b-and-ginkgolide-k
#8
Hong Zhang, Yan-Ping Luo, Ze-Yu Cao, Xin-Zhuang Zhang, Liang Cao, Zhen-Zhong Wang, Wei Xiao
To investigate the best active compatibility of ginkgolide A, B and K (GA,GB,GK). The effects of GA, GB, GK alone, combinations of each two of them, and combinations of these three components on platelet-activating factor (PAF)-induced platelet aggregation activity and rat cerebral ischemia reperfusion model (tMCAO) were compared in this study. Different compatibilities of GA, GB and GK could significantly reduce the maximum aggregation rate of PAF-induced platelet aggregation, and the effect was most obvious in combination of the three...
April 2018: Zhongguo Zhong Yao za Zhi, Zhongguo Zhongyao Zazhi, China Journal of Chinese Materia Medica
https://www.readbyqxmd.com/read/29723256/renal-protective-effect-of-antiplatelet-therapy-in-antiphospholipid-antibody-positive-lupus-nephritis-patients-without-antiphospholipid-syndrome
#9
Hironari Hanaoka, Harunobu Iida, Tomofumi Kiyokawa, Yukiko Takakuwa, Takahiro Okazaki, Hidehiro Yamada, Shoichi Ozaki, Kimito Kawahata
OBJECTIVE: We sought to evaluate the effect of antiplatelet therapy in addition to conventional immunosuppressive therapy for lupus nephritis (LN) patients positive for antiphospholipid antibodies (aPL) without definite antiphospholipid syndrome (APS). METHODS: Patients with biopsy-proven LN class III or IV were retrospectively evaluated. We selected patients positive for anticardiolipin antibody (aCL) or lupus anticoagulant (LA) who did not meet the criteria for a diagnosis of APS...
2018: PloS One
https://www.readbyqxmd.com/read/29720261/efficacy-and-safety-of-adding-rivaroxaban-to-the-anti-platelet-regimen-in-patients-with-coronary-artery-disease-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials
#10
Jun Yuan
BACKGROUND: Rivaroxaban, a direct factor Xa inhibitor, has seldom been used in patients with coronary artery disease. In this analysis, we aimed to systematically compare the efficacy and safety of rivaroxaban in addition to the anti-platelet regimen in patients with coronary artery disease. METHODS: Online databases (MEDLINE, EMBASE, Cochrane database, www.ClinicalTrials.gov and Google scholar were searched for randomized controlled trials which were exclusively based on patients with coronary artery disease; and which compared efficacy (cardiovascular outcomes) and safety (bleeding outcomes) outcomes with the addition of rivaroxaban to the other anti-platelet agents...
May 2, 2018: BMC Pharmacology & Toxicology
https://www.readbyqxmd.com/read/29720092/post-percutaneous-coronary-interventional-adverse-cardiovascular-outcomes-and-bleeding-events-observed-with-prasugrel-versus-clopidogrel-direct-comparison-through-a-meta-analysis
#11
Pravesh Kumar Bundhun, Feng Huang
BACKGROUND: Due to limitations associated with clopidogrel following percutaneous coronary intervention (PCI), other newer oral anti-platelet agents are being studied. We aimed to systematically carry out a direct comparison of outcomes observed with prasugrel versus clopidogrel following PCI. METHODS: Common online searched databases (The Cochrane library, EMBASE, MEDLINE and Google scholar) were used to retrieve relevant publications. Primary endpoints were the adverse cardiovascular outcomes...
May 2, 2018: BMC Cardiovascular Disorders
https://www.readbyqxmd.com/read/29715499/new-and-upcoming-treatments-in-antiphospholipid-syndrome-a-comprehensive-review
#12
REVIEW
Flavio Signorelli, Gustavo Guimarães Moreira Balbi, Vinicius Domingues, Roger Abramino Levy
Current therapeutic recommendations for thrombosis prevention in patients with antiphospholipid syndrome (APS) are limited to anticoagulation with vitamin K antagonists (VKA) or heparins and to anti-platelet aggregating agents. Maintaining optimized anticoagulation to prevent recurrent thrombosis or bleeding remains a therapeutic challenge. Although there are important ongoing trials with direct oral anticoagulants, they still aim the same target. New insights about pathophysiology in APS have revealed a myriad of potential pathways to be investigated as treatment targets...
April 28, 2018: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://www.readbyqxmd.com/read/29713353/the-norpurpureine-alkaloid-from-annona-purpurea-inhibits-human-platelet-activation-in-vitro
#13
Gabriela Sánchez, Omar Estrada, Giovana Acha, Alfonso Cardozo, Franshelle Peña, Marie Christine Ruiz, Fabián Michelangeli, Claudia Alvarado-Castillo
Background: The leaves of Annona purpurea have yielded several alkaloids with anti-aggregation activities against rabbit platelets. This is promising in the search for agents that might act against platelets and reduce the incidence of cardiovascular diseases. Since significant differences in platelet function have been reported between human and animal platelets, a study focusing on the effect of A. purpurea extracts against human platelet activation is necessary. Methods: The compounds in an A...
2018: Cellular & Molecular Biology Letters
https://www.readbyqxmd.com/read/29707148/dual-antiplatelet-therapy-with-clopidogrel-and-aspirin-increases-mortality-in-4t1-metastatic-breast-cancer-bearing-mice-by-inducing-vascular-mimicry-in-primary-tumour
#14
Marta Smeda, Anna Kieronska, Bartosz Proniewski, Agnieszka Jasztal, Anna Selmi, Krystyna Wandzel, Agnieszka Zakrzewska, Tomasz Wojcik, Kamil Przyborowski, Katarzyna Derszniak, Marta Stojak, Dawid Kaczor, Elzbieta Buczek, Cezary Watala, Joanna Wietrzyk, Stefan Chlopicki
Platelet inhibition has been considered an effective strategy for combating cancer metastasis and compromising disease malignancy although recent clinical data provided evidence that long-term platelet inhibition might increase incidence of cancer deaths in initially cancer-free patients. In the present study we demonstrated that dual anti-platelet therapy based on aspirin and clopidogrel (ASA+Cl), a routine regiment in cardiovascular patients, when given to cancer-bearing mice injected orthotopically with 4T1 breast cancer cells, promoted progression of the disease and reduced mice survival in association with induction of vascular mimicry (VM) in primary tumour...
April 3, 2018: Oncotarget
https://www.readbyqxmd.com/read/29703466/anti-platelet-treatments-in-cancer-basic-and-clinical-research
#15
Paolo Gresele, Marco Malvestiti, Stefania Momi
Over the past few decades the central role that platelets play in cancer development and progression, and especially in metastasis, has been elucidated. The molecular mechanisms responsible for initiating and mediating tumor cell-induced platelet aggregation and secretion have been largely unravelled. Considerable mechanistic insight into how platelets contribute to tumor angiogenesis, immunoevasion and cancer cell invasion have been clarified and, consequently, platelets have been identified as potential new drug targets for cancer therapy...
April 2018: Thrombosis Research
https://www.readbyqxmd.com/read/29702713/predictors-of-bleeding-in-patients-with-symptomatic-peripheral-artery-disease-a-cohort-study-using-the-health-improvement-network-in-the-united-kingdom
#16
Lucía Cea Soriano, F Gerry R Fowkes, Alaster M Allum, Saga Johansson, Luis A García Rodriguez
The purpose of this analysis was to assess potential predictors of intra-cranial bleeding (ICB) and gastrointestinal bleeding (GIB) in patients with symptomatic peripheral artery disease (PAD) in UK primary care. Patients with symptomatic PAD diagnosed from 2000 to 2010 were identified from The Health Improvement Network (THIN; N  = 28,484). A nested case-control analysis, adjusted for potential confounders, was performed to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for potential predictors of ICB or GIB...
April 27, 2018: Thrombosis and Haemostasis
https://www.readbyqxmd.com/read/29696533/tirofiban-positively-regulates-%C3%AE-1-integrin-and-favours-endothelial-cell-growth-on-polylactic-acid-biopolymer-vascular-scaffold-bvs
#17
Arturo Giordano, Simona Romano, Nicola Corcione, Giacomo Frati, Giuseppe Biondi Zoccai, Paolo Ferraro, Stefano Messina, Stefano Ottolini, Maria Fiammetta Romano
An unexpectedly high incidence of thrombosis in patients that received the polylactic acid bioresorbable vascular scaffold (BVS) suggests a delayed/incomplete endothelial repair with this stent. The anti-platelet agent tirofiban stimulates endothelial cell migration and proliferation, mediated by VEGF production. We investigated the tirofiban effect on the migration and adhesion of endothelial cells to BVS, in vitro. We performed human umbilical endothelial cell (HUVEC) cultures in the presence of BVS. Tirofiban, similarly to VEGF, increased the ability of HUVEC to grow on the vascular scaffold, compared to unstimulated or abciximab-treated cells...
April 25, 2018: Journal of Cardiovascular Translational Research
https://www.readbyqxmd.com/read/29688733/drug-use-for-secondary-prevention-of-cardiovascular-diseases-in-golestan-iran-results-from-the-golestan-cohort-study
#18
Mahdi Nalini, Sadaf G Sepanlou, Akram Pourshams, Hossein Poustchi, Maryam Sharafkhah, Hossein Bahrami, Farin Kamangar, Reza Malekzadeh
BACKGROUND: Little is known about secondary prevention of cardiovascular diseases, using cardio-protective drugs, in the community-level, especially in low- and middle-income countries. We aimed to assess main drug use and its predictors in Northeast of Iran. METHODS: This is a cross-sectional analysis on the Golestan Cohort Study data (2004-2008) with 50 045 participants. We assessed drug use in those with a history of ischemic heart disease (IHD) or stroke, recorded by face-to-face interviews...
March 1, 2018: Archives of Iranian Medicine
https://www.readbyqxmd.com/read/29680945/cilostazol-is-effective-to-prevent-stroke-associated-pneumonia-in-patients-receiving-tube-feeding
#19
Shizuka Netsu, Atsushi Mizuma, Masaki Sakamoto, Sachiko Yutani, Eiichiro Nagata, Shunya Takizawa
Stroke-associated pneumonia (SAP) is a frequent complication in acute ischemic stroke (IS) patients, especially those receiving tube feeding (TF). In this retrospective study, we investigated whether or not cilostazol, a pluripotent phosphodiesterase III-specific inhibitor with anti-platelet and vasculogenic effects, can prevent SAP in these patients and reduce their duration of stay in intensive care unit/hospitalization. We recruited 158 IS patients receiving TF. Patients' characteristics (including age, gender, past history), National Institute of Health Stroke Scale and serum albumin level on admission, concomitant medications associated with SAP prevention (including cilostazol), and stroke characteristics (bilateral subcortical white matter lesion, brainstem involvement, large infarction, and asymptomatic hemorrhagic infarction) were compared between the SAP(-) and SAP(+) groups...
April 21, 2018: Dysphagia
https://www.readbyqxmd.com/read/29676226/is-a-variability-of-platelet-inhibitory-effect-of-anti-platelet-agents-important-for-predicting-new-lesion-in-atherothrombotic-stroke
#20
Jin-Man Jung, Jin-Woo Park, Sung Un Kim, Do-Young Kwon, Moon-Ho Park
No abstract text is available yet for this article.
January 1, 2018: International Journal of Stroke: Official Journal of the International Stroke Society
keyword
keyword
10531
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"